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Background: Efficacy of neuroprotective treatments for ischemic stroke was not convincingly demonstrated in
clinical phase III trials so far, whereas some preceding early phase studies found neuroprotection to be beneficial.
We aimed to determine the frequency with which phase III studies are preceded by positive early phase studies,
and to identify characteristics of early phase studies that are associated with correct prediction of phase III studies.
Methods: We identified phase III studies and corresponding early phase studies of neuroprotective treatments for
stroke. Data on study characteristics of early phase trials were extracted and compared between studies that were
classified according to their results as “false positive” and “true neutral” using logistic regression analysis.
Results: Forty-six phase III studies and 59 corresponding early phase studies were identified. Only one phase III
study was positive and this study was followed by a larger negative study. Twenty-two (37.3%) early phase studies
were considered to be false positive and 37 (62.7%) to be true neutral. None of the early phase study characteristics
were significantly associated with correct prediction of phase III studies.
Conclusions: More than one third of early phase studies on neuroprotective stroke treatments are false positive.
Neither the results nor specific study design characteristics of early phase stroke studies reliably predict success in
phase III trials. Further efforts are needed to improve early phase studies regarding its predictability and to identify
those early studies that should be advanced to phase III trials.
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Neuroprotective treatments for stroke were considered to
be promising for clinical development. This process usu-
ally progresses from phase I to phase II to phase III stud-
ies. The primary objectives of phase I studies are to assess
the safety and tolerability of a treatment in a small group
of healthy participants or patients. Some phase I studies
also intend to gain early evidence of effectiveness [1].
Phase II trials evaluate the efficacy of a drug and further
investigate its safety in a larger group of patients. In phase
III trials a therapeutic intervention is compared to stand-
ard treatment to confirm its efficacy. Phase III studies are
usually required for approval by regulatory agencies and* Correspondence: minnerup@uni-muenster.de
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unless otherwise stated.for adoption of new therapies. Hundreds to thousands of
patients are enrolled in phase III studies making these time
consuming and expensive. So far, numerous neuroprotec-
tion phase III trials for ischemic stroke have been com-
pleted, none of which demonstrated unequivocal efficacy of
the investigated treatment [2]. In contrast, some preceding
early phase (phase I and II) studies found neuroprotective
treatments to be beneficial regarding clinical outcome.
We aimed to determine the frequency with that phase
III studies are preceded by positive early studies, and to
identify study characteristics of early phase studies that are
associated with correct prediction of subsequent phase III
studies. Determination of these study characteristics can
help to improve the trial design of future phase I and II
stroke studies. Moreover, it might allow to evaluate the re-
sults of existing early phase studies regarding the capabil-
ity for successful progression to phase III.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Identification and data extraction of phase III studies
For identification of phase III clinical trials on neuropro-
tective treatments for acute ischemic stroke we systemat-
ically searched the databases Clinicaltrials.gov (searched in
November 2012) and The Internet Stroke Center (searched
in November 2012) [1,3]. The search strategy for Clinical-
trials.gov used the terms “Closed Studies” for the search
term ‘Recruitment’, “All studies” for the search term ‘Study
Result’, “Interventional Studies” for the search term ‘Study
Type’, and “Phase III” for the search term ‘Phase’. For
search in The Internet Stroke Center we used the terms
“Completed” and “Terminated” for the search term ‘Sta-
tus’ and the term “Phase 3” for the search term ‘Phase’. In
addition, review articles on clinical acute stroke studies
were reviewed for phase III trials [2,4-6]. To include only
studies on acute stroke, the search was limited to those
studies with treatment initiation within 72 hours after
stroke onset. Only studies on neuroprotection were in-
cluded. Studies of thrombolytic, antithrombotic, or antihy-
pertensive agents without neuroprotective properties were
excluded. Publications of thus identified phase III studies
were retrieved and data were extracted. Only articles in
English were included. When studies were not published
in full data were obtained from the Internet Stroke Center
or from Cochrane Stroke Group reviews. Results of phase
III studies were judged to be either “positive”, “neutral” or
“negative”. A study was defined to be “positive” if the pri-
mary end points were reached or if the neuroprotective
treatment was superior to the placebo treatment regarding
functional recovery or mortality in cases the primary end
point was not stated. Additional data that were retrieved
include the maximum time of treatment initiation after
symptom onset, the dose and route of administration of
the neuroprotective treatment, and the number of patients
included in the study.
Identification, selection, and data extraction of early
phase studies
Phase I and phase II studies of neuroprotective therapies
of identified phase III studies were searched using the
database Pubmed (searched at November 2012). This
strategy included the words “stroke” or “ischemia” or “in-
farct” AND “drug name” or “abbreviated drug name”. In
addition, articles of phase III studies were searched for
preceding phase I and phase II studies. Except the terms
“Phase I” and “Phase II” for the search term ‘Phase’ the
same search strategy as described for phase III studies was
used for searching the databases Clinicaltrials.gov (searched
in November 2012) and The Internet Stroke Center
(searched in November 2012). Only articles in English were
included. In the absence of full publication abstracts were
analyzed when all required data were available by the Inter-
net Stroke Center or from Cochrane Stroke Groupreviews. Studies were determined as “positive” or “neutral”
or “negative” regarding treatment efficacy as judged by the
authors in the publication [7]. Moreover, data on the fol-
lowing characteristics of phase I and phase II studies were
extracted: Number of patients enrolled, trial setting (single-
center or multicenter), randomization, blinded outcome as-
sessment, industry sponsoring, dose–response investigation,
time point of outcome assessment, use of imaging end-
points (e.g. infarct size), and use of the same therapeutical
time window, the same dose and the same route of admin-
istration as in the corresponding phase III trial. The selec-
tion of considered study characteristics was based on
previously published articles on the design of acute stroke
studies [7,8].
Statistical analysis
Early phase studies (phase I and II) were assigned to their
corresponding phase III trial. As early clinical stroke stud-
ies were frequently not clearly specified as phase I or
phase II studies we subsumed these in one category. For
treatments of which more than one phase III trials exists,
phase I and phase II studies were allocated to their imme-
diately following phase III studies. Phase I and II studies
were classified as “true neutral” or “false positive”. Those
with positive results and subsequent negative phase III
studies were classified as “false positive” and those with
neutral results and subsequent negative phase III studies
were classified as “true neutral”. No phase I or phase II
studies with negative results could be identified. As conflict-
ing results of phase III studies on the efficacy of NXY-059
exist, the larger (neutral) Stroke-Acute Ischemic NXY
Treatment Trial (SAINT) II trial was used as reference
for the classification of phase I and phase II studies on
NXY-059. For comparison of study characteristics be-
tween “false positive” and “true neutral” phase I and II
studies we applied unadjusted (crude) logistic regression
analysis and a multivariable model that included all
study characteristics simultaneously. The level of sig-
nificance was defined as a two-tailed P < 0.05. The ana-
lyses were carried out using SAS 9.2 and the Statistical
Package of Social Sciences (version 21).
Results
Identified phase III studies and their results
The search strategy yielded 153 studies by searching the
database Clinicaltrials.gov and 165 studies by searching
the database The Internet Stroke Center. Seven further
studies were identified by searching review articles on clin-
ical acute stroke studies. Of the identified studies 46 phase
III studies fulfilled the inclusion criteria (Table 1). In these
studies 34 different neuroprotective treatments were in-
vestigated. The studies were published between 1988 and
2012. Four studies were not published (POST-010 and
POST-011, Eliprodil Phase III, Fosphenytoin Phase III,
Table 1 Identified phase III studies
Study acronym/study title Year of publication Intervention No. of subjects Result
PAIS 2009 Acetaminophen 1400 Neutral
AHAIS 2001 Aptiganel 628 Neutral
BEST 1988 Atenolol, Propanolol 302 Neutral
POST-010 and POST-011 * BMS-204352 1978 Neutral
SCAST 2011 Candesartan 2004 Neutral
Cervene phase 3 2000 Cervene (Nalmefene) 368 Neutral
Citicoline ECCO 2000 2001 Citicoline 899 Neutral
Citicoline 007 1999 Citicoline 394 Neutral
ICTUS 2012 Citicoline 2298 Neutral
CLASS 1999 Clomethiazole 1360 Neutral
CLASS-I 2002 Clomethiazole 1198 Neutral
EGASIS 2006 Diazepam 880 Neutral
MACSI 2013 DP-b99 446 Neutral
EAIS 1998 Ebselen 302 Neutral
EAST 2009 Edaravone 814 Neutral
Eliprodil phase III * Eliprodil 483 Neutral
EAST 2001 Enlimomab 625 negative
ESS 2009 Epoetin Alfa 522 Neutral
Fiblast phase III 2002 Fibroblast growth factor 286 Neutral
FIST 1996 Flunarizine 331 Neutral
Fosphenytoin phase III * Fosphenytoin 462 Neutral
GAIN International 2000 Gavestinel (GV150526) 1804 Neutral
GAIN Americas 2001 Gavestinel (GV150526) 1367 Neutral
EST 1994 GM1 ganglioside 792 Neutral
SASS 1994 GM1 ganglioside 287 Neutral
IASSH 1989 GM1 ganglioside 502 Neutral
ASCLEPIOS 1994 Israpidine 357 Neutral
LUB-INT-13 2000 Lubeluzole 1786 Neutral
Lub 1997 Lubeluzole 721 Neutral
IMAGES 2004 Magnesium 2589 Neutral
PRISTINE 1996 Naftidrofuryl 620 Neutral
ANS 1992 Nimodipine 1064 Neutral
INWEST 1994 Nimodipine 295 negative
TRUST 1990 Nimodipine 1215 Neutral
VENUS 2001 Nimodipine 454 Neutral
SAINT II 2007 NXY-059 3306 Neutral
SAINT I 2006 NXY-059 1722 positive
RREACT 2007 ONO-2506, Arundic acid 841 Neutral
PASS 1997 Piracetam 927 Neutral
mRECT 2009 Repinotan 681 Neutral
ASSIST 2000 Selfotel (CGS19755) 567 Neutral
RANTTAS 1996 Tirilazad mesylate 556 Neutral
RANTTAS II 1998 Tirilazad mesylate 126 Neutral
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Table 1 Identified phase III studies (Continued)
NEST-2 2009 Transcranial laser therapy 660 Neutral
ASTIN 2003 UK279,276 966 Neutral
ARTIST+ * YM872 312 Neutral
*Study was not published, information on study was obtained from the Internet Stroke Center.
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tained from the Internet Stroke Center database. The me-
dian number of patients enrolled in the included studies
was 670.5 (range 126 to 3306). Forty-three studies were
neutral (active treatment and control not significantly dif-
ferent), two studies were negative (control superior to ac-
tive treatment), and only one study was positive (active
treatment superior to control). However, the only positive
study (SAINT I) was followed by a larger negative study
(SAINT II).
Early phase study characteristics and their association
with phase III results
Fifty-nine early phase studies, investigating 26 neuroprotec-
tive treatments were identified. The characteristics of these
studies are shown in Table 2. For 8 treatments (combin-
ation of Atenolol and Propanolol, BMS-204352, Diazepam,
Eliprodil, Enlimomab, Fibroblast Growth Factor, Fosphe-
nytoin, Israpidine) evaluated in phase III studies no pre-
ceding randomized phase I/II trials were identified. The
median number of subjects enrolled in phase I/II studies
was 92 (range 25 to 725). More than half (61.0%) of the
studies were sponsored by industry. The majority of stud-
ies were multicenter studies (69.5%). Randomization was
reported in 57 (96.6%) and blinded outcome assessment inTable 2 Characteristics of early phase studies and association
Study characteristics All early phase studies
(n = 59)
No. of subjects, median (IQR) 92.0 (46.0-176.0)
Industry sponsored, n (%) 36 (61.0)
Multicentered, n (%) 41 (69.5)
Randomized, n (%) 57 (96.6)
Blinded outcome assessment, n (%) 52 (88.1)
Dose–response investigated, n (%) 16 (27.1)
Use of imaging endpoint, n (%) 15 (25.4)
Duration of follow-up for endpoints*,
median (IQR), days
87.0 (30.0-90.0)
Same characteristics in phase I/II studies as in
subsequent phase III studies
Same therapeutic time window, n (%) 19 (32.2)
Same dose, n (%) 29 (49.2)
Same route of administration, n (%) 50 (84.7)
IQR, interquartile range, aOR (adjusted odds ratio) for comparison of study characte
logistic regression analysis, CI, confidence interval, *one study did not report the ex
length of hospital stay in this study was 9.5 days in the verum group and 11.2 days52 (88.1%) of the included phase I/II studies. In 16 (27.1%)
studies the dose–response relationship was explored and in
15 (25.4%) studies an imaging endpoint in addition to clin-
ical endpoints was used. The median duration of follow-up
for endpoints was 87 days (range 3 to 365). Compared to
corresponding phase III trials in phase I and phase II stud-
ies the same therapeutical time window, the same dose, and
the same route of administration was used in 18 (32.2%),
29 (49.2%), and 50 (84.7%), respectively.
Twenty-two (37.2%) early phase studies were considered
to be positive and 37 (62.7%) to be neutral. Characteristics
of early phase studies and their associations with predic-
tion of phase III study results are shown in Table 2. We
found no study characteristic of early phase studies to be
significantly associated with correct prediction of phase III
results, neither in a univariate nor in multivariable logistic
regression analysis.
In one study endpoints were determined at discharge
and mean length of hospital stay was reported to be
9.5 days in verum treated patients and 11.2 days in the
placebo group. Therefore duration to follow-up for
endpoints in this study was estimated to be ten days
(results of the regression model remained unchanged
when duration to follow-up of this study was largely








100.0 (46.0-157.0) 91.5 (49.3-197.5) 1.00 [0.99-1.00] 0.713
25 (67.6) 11 (50.0) 1.73 [0.40-7.54] 0.465
28 (75.7) 13 (59.1) 1.48 [0.28-7.87] 0.643
35 (94.6) 22 (100.0) 0.00 [0.00-∞] 1.000
34 (91.9) 18 (81.8) 3.95 [0.26-60.30] 0.323
12 (32.4) 4 (18.2) 1.25 [0.26-6.07] 0.786
8 (21.6) 7 (31.8) 0.46 [0.12-1.81] 0.263
90.0* (30.0-90.0) 41.0 (28.0-90.0) 1.00 [0.99-1.01] 0.722
10 (27.0) 9 (40.9) 0.69 [0.18-2.68] 0.588
18 (48.6) 11 (50.0) 0.94 [0.28-3.14] 0.916
34 (91.9) 16 (72.7) 3.33 [0.59-18.86] 0.174
ristics between “false positive” and “true neutral” studies in a multivariable
act duration of follow-up as endpoints were determined at discharge (mean
in the placebo group).
Minnerup et al. Experimental & Translational Stroke Medicine 2014, 6:2 Page 5 of 6
http://www.etsmjournal.com/content/6/1/2Discussion
So far no phase III study convincingly demonstrated the
efficacy of a neuroprotective treatment for acute ische-
mic stroke. In contrast more than one third of early
phase studies included in our analysis reported neuro-
protectants to be beneficial and thus yielded false posi-
tive results. We found no single characteristic of early
phase studies to be significantly associated with correct
prediction of phase III study results.
The question remains why promising results from
early phase studies were not reproduced in phase III
studies. The majority of analyzed early phase studies
shared relevant features with phase III studies, such as
randomization, blinded outcome assessment, and mul-
ticentricity. The main difference between early phase
and phase III studies remains the number of enrolled
patients, thus potentially being the reason for the dis-
crepant results. This assumption is emphasized by re-
sults of a previous analysis of clinical stroke studies
which found a decreased likelihood of a positive trial
results with increasing sample size [7].
Different approaches were used to evaluate which
early studies results can be considered as encouraging
and should therefore be advanced to phase III. The
method developed by Mandava and Kent is based on
the assumption of an imbalance in randomization of
baseline factors contributes to misleading results of
early phase studies [4). In their model randomization
errors are minimized by comparisons with an outcome
function derived from a large number of pooled con-
trol arms. Using this model the failure of the SAINT II
and of the Abciximab Emergent Stroke Treatment
Trial (AbESTT) could have been predicted [4]. Al-
though promising, this model has, however, not been
evaluated prospectively so far.
The method used in our study was previously applied
on cancer studies [9,10]. In an analysis of 351 early
phase studies on targeted therapies for cancer multiple
institution participation, industry sponsoring, and a
shorter time period between publication of early phase
and phase III studies were predictive factors for suc-
cess in subsequent phase III trials [9]. In another study
on chemotherapies for cancer treatment, however,
none of the early phase study characteristics signifi-
cantly predicted results of phase III studies [10]. In
contrast to phase III studies on ischemic stroke a re-
markable number of cancer phase III studies included
in the analyses were positive. Hence the method to
determine characteristics of phase II studies that pre-
dict success in subsequent studies cannot be simply
adopted for stroke trials. We therefore slightly modi-
fied this approach and aimed to identify characteristics
that are associated with “false positive” and “true neu-
tral” results.A limitation of our analysis might be bias caused by
unpublished studies [5,7]. However, to reduce the impact
of publication bias on our results we also included stud-
ies that were not published in full and obtained data
from the Internet Stroke Center and from Cochrane Stroke
Group reviews. A further limitation of our analysis is the
fact that early phase studies are usually not powered to de-
tect differences of the clinical outcome. However, the re-
sults on efficacy in early studies are frequently the basis
for testing in phase III trials.
Conclusion
Our study shows that more than one third of early
phase studies on neuroprotective treatments for stroke
are false positive. We found no single early phase study
characteristic whose presence or absence reliable pre-
dicts success in phase III trials. Further efforts are
needed to improve early phase stroke studies regarding
its predictability and to identify those early studies that
should be advanced to phase III trials.
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